Anti-Serpin-B1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the amino-terminal region of mature human Serpin-B1 (P30740), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Monkey, Dog, Pig
UniProt
P30740
Size
100ug
Cat. #
RP1SerpinB1

In stock

SKU
RP-SerpinB1

Options

As low as: $130.00

Target Overview

Serpin-B1 (UniProt P30740), also known as leukocyte elastase inhibitor (LEI) or monocyte/neutrophil elastase inhibitor (M/NEI), is a 379-residue member of the clade B (ov-serpin) family of serine protease inhibitors. It is one of the most abundant proteins in neutrophil cytoplasm and is also expressed in monocytes, macrophages, and epithelial cells of mucosal surfaces. Like other intracellular serpins, Serpin-B1 lacks a classical signal peptide but can be released into the extracellular space during cell stress, degranulation, or NETosis. Functionally, Serpin-B1 is a broad-specificity inhibitor of neutrophil serine proteases, forming covalent complexes with neutrophil elastase (ELANE), cathepsin G (CTSG), and proteinase-3 (PRTN3), and additionally inhibiting chymase, chymotrypsin, and kallikrein-3. It also blocks granzyme H (GZMH) intracellularly and dampens activation of the inflammatory caspases CASP1, CASP4, and CASP5 by suppressing CARD oligomerization. Through these activities Serpin-B1 protects the host cell from collateral damage when granule proteases are mis-localized during infection or injury, and helps set thresholds for inflammasome-driven cytokine release. Secreted Serpin-B1 has additionally been reported to promote pancreatic beta-cell proliferation in a protease-inhibition–dependent manner. For researchers studying innate immunity, neutrophil biology, inflammatory lung disease, granule release, or beta-cell expansion, Serpin-B1 is a relevant readout of both protease load and cellular protective capacity. Two SKUs (RP1SerpinB1 and RP2SerpinB1) are offered, both raised in rabbit against the amino end of mature Serpin-B1.

Background

Serpin-B1 sits at the intersection of protease control and innate immune regulation. Neutrophil serine proteases (NSPs) such as elastase, cathepsin G and proteinase-3 are essential for microbial killing but, when leaked from azurophilic granules into the cytoplasm or extracellular milieu, drive tissue destruction in conditions ranging from acute lung injury to chronic obstructive pulmonary disease and vasculitis. Serpin-B1 is the dominant intracellular brake on these enzymes, acting through the classical serpin suicide-substrate mechanism in which the reactive center loop is cleaved and the protease is trapped in a covalent acyl-enzyme complex. Beyond NSP inhibition, Serpin-B1 has been assigned non-canonical roles in inflammasome regulation, where it constrains CASP1/4/5 activation, and in cytotoxic lymphocyte biology, where it neutralizes intracellular granzyme H. Loss-of-function studies in mice show neutrophil survival defects and exaggerated inflammatory responses to bacterial challenge, consistent with a homeostatic rather than purely antimicrobial role. Reported secretion of Serpin-B1 and its mitogenic effect on pancreatic beta-cells has also drawn interest from the metabolic disease field. Recent literature continues to expand the disease contexts in which Serpin-B1 is implicated. Hao et al. (2026, Hypertension) reported that macrophage-derived Serpin-B1 blunts the inflammatory phenotype of pulmonary artery smooth muscle cells and protects against hypoxia-induced pulmonary hypertension, identifying macrophage-to-PASMC crosstalk as a therapeutic axis. Yan et al. (2026, Vet Microbiol) showed that SERPINB1 promotes porcine deltacoronavirus replication by targeting the viral accessory protein NS7a, suggesting a proviral role that diverges from its protective host functions. Serpin-B1 has also surfaced in unbiased proteomic surveys of dental caries progression (Vidal et al., 2026) and saliva from Jalili syndrome patients (Rattanapornsompong et al., 2026), reflecting its abundance in mucosal and granulocyte-rich secretions and its utility as a biomarker of neutrophilic activity.

References

  1. Hao J et al (2026) Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension. Hypertension. PubMed · doi:10.1161/HYPERTENSIONAHA.125.25832
  2. Yan J et al (2026) SERPINB1 promotes porcine deltacoronavirus replication by targeting the viral accessory protein NS7a. Vet Microbiol. PubMed · doi:10.1016/j.vetmic.2025.110869
  3. Vidal CMP et al (2026) Stage-Specific Proteomic Profiles in Dental Caries. J Dent Res. PubMed · doi:10.1177/00220345251392212
  4. Rattanapornsompong K et al (2026) Saliva Proteomics Shows Immune Activation and Metabolic Shifts in Female Jalili Syndrome Patients. Oral Dis. PubMed · doi:10.1111/odi.70273
  5. Liu L et al (2026) SLC22A4 as a candidate regulator linking immunity and ferroptosis in septic shock. Mol Immunol. PubMed · doi:10.1016/j.molimm.2026.06.007

Additional Specifications

Gene Symbol SerpinB1
UniProt ID P30740
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Monkey, Dog, Pig
Pack Size 100ug
Immunogen (Â Amino end mature Serpin-B1)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1-51.
Immunogen (Reactive Center Loop (RCL))Immunogen is proprietary and confidential. Immunogen generated in amino acid region 334-374.
Alternate Names Leukocyte elastase inhibitor, LEI, Monocyte/neutrophil elastase inhibitor, M/NEI, EI, Peptidase inhibitor 2, PI-2, Serpin B1, SERPINB1

Frequently Asked Questions

What molecular weight should I expect for Serpin-B1 on a Western blot?

Native Serpin-B1 runs at approximately 42-45 kDa on reducing SDS-PAGE, consistent with the 379-residue mature protein (predicted ~42.7 kDa). In neutrophil and monocyte lysates the cleaved form (RCL-cleaved, ~38-40 kDa) is often visible as a lower band, particularly if samples were not fully protease-inhibited during lysis. SDS-stable covalent complexes with neutrophil elastase, cathepsin G, or proteinase-3 can also appear at ~70-95 kDa. If you see only high-MW smearing, suspect incomplete reduction or complex formation; boil 5 minutes in fresh DTT/β-ME-containing Laemmli buffer.

What dilution should I start with for Western blot, and what lysate loading works?

Start at 1:1000 in 5% non-fat milk or BSA/TBST, overnight at 4°C. Serpin-B1 is highly abundant in neutrophils, so 10-20 µg of whole-neutrophil lysate is usually sufficient; for monocytes, macrophages, or epithelial lines load 30-50 µg. For low-expressing tissues or transfected systems, titre between 1:500 and 1:2000 against your specific lysate. The 100 µg pack at 1:1000 supports roughly 100 mini-blots at 10 mL working volume. Milk works well; we have not seen phospho-epitope interference, so BSA is not required.

Does this antibody cross-react with other clade B serpins like SerpinB6 or SerpinB9?

The immunogen targets sequence within human SERPINB1 that shares limited identity with paralogues SerpinB6, B8, and B9 in the reactive centre loop and shutter region, but clade B serpins do share a conserved fold. We have not observed cross-reactivity with recombinant SerpinB6 or B9 on Western blot, but if you are working in tissues co-expressing multiple ov-serpins (e.g., spleen, bone marrow), include a SERPINB1-knockdown or knockout control. SerpinB1-/- mouse neutrophils are a clean negative control once mouse reactivity is confirmed in your hands.

Is this antibody validated for mouse or rat samples?

Validation to date is on human samples (neutrophil lysate, HL-60, monocyte preparations). Reactivity with mouse, rat, pan, monkey, dog, and pig is predicted based on sequence alignment of the immunogen region, but has not been formally validated in-house. Mouse Serpinb1a shares ~70% identity with human SERPINB1 across the immunogen; expect detection but titre your dilution and include a positive control (mouse bone marrow neutrophils run high). For rat, we suggest a pilot WB at 1:500 and 1:1000 before scaling to IHC.

What positive control should I use to confirm the antibody is working?

Human peripheral blood neutrophils are the gold-standard positive control — Serpin-B1 is among the most abundant cytoplasmic proteins, and 5-10 µg of lysate gives a strong 42-45 kDa band. HL-60 cells differentiated toward granulocytes with DMSO or ATRA also express robust Serpin-B1. U937 (monocytic) shows moderate expression. For tissue, human bone marrow, spleen, and lung (alveolar macrophage-rich) work well for IHC. Avoid using whole blood without leukocyte enrichment, as plasma serpins (SerpinA1, A3) dominate and can confuse interpretation.

How should I prepare neutrophil lysates to avoid Serpin-B1 degradation or complex artefacts?

Neutrophils carry abundant active serine proteases that will cleave Serpin-B1's reactive centre loop the moment cells lyse, generating the ~40 kDa cleaved form and high-MW covalent complexes. Lyse directly into boiling 1× Laemmli buffer with DTT, or use ice-cold RIPA supplemented with a broad protease inhibitor cocktail plus 1 mM PMSF and 10 µM E-64. Avoid freeze-thaw of native lysates. For complex analysis (e.g., Serpin-B1:elastase), lyse without reducing agent first, then split and add DTT for parallel reduced/non-reduced blots.

Can I use this antibody for IHC on FFPE tissue, and what antigen retrieval works?

Yes — the antibody is validated for IHC. For FFPE sections, heat-induced epitope retrieval in 10 mM citrate buffer pH 6.0 (20 minutes at sub-boiling) is our standard starting condition; Tris-EDTA pH 9.0 also works and may give cleaner background on lung and gut sections. Start at 1:100-1:200 for IHC-P and titre. Expect strong cytoplasmic staining in neutrophils, monocytes, and mucosal epithelium. Tonsil and bone marrow are reliable control tissues. Include a no-primary control; endogenous peroxidase in granulocytes can give false signal if not quenched adequately.

How should the antibody be stored, and is it stable to repeated freeze-thaw?

Supplied at 1 mg/mL in PBS with 0.02% sodium azide and 50% glycerol. Store at -20°C for long-term; the glycerol formulation means it will not freeze solid, so aliquoting is optional but recommended if you anticipate frequent use over months. For routine bench work, a 4°C working aliquot is stable for at least 4 weeks. Avoid repeated freeze-thaw of the main stock — more than 5 cycles can reduce titre, particularly for IHC applications. Do not store diluted working solutions; prepare fresh from concentrated stock for each experiment.

Western blot validation for RP-SerpinB1 — 1 panel across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Serpin-B1: Amino end mature Serpin-B1 — WB validation
WB · Panel 1 Serpin-B1: Amino end mature Serpin-B1

Custom validation studies available on request — contact us.

Also known as:

  • Leukocyte elastase inhibitor
  • LEI
  • Monocyte/neutrophil elastase inhibitor
  • M/NEI
  • EI
  • Peptidase inhibitor 2
  • PI-2
  • Serpin B1
  • SERPINB1
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →